Toggle light / dark theme

Machine enhanced humans — or cyborgs as they are known in science fiction — could be one step closer to becoming a reality, thanks to new research Lieber Group at Harvard University, as well as scientists from University of Surrey and Yonsei University.

Researchers have conquered the monumental task of manufacturing scalable nanoprobe arrays small enough to record the inner workings of human cardiac cells and primary neurons.

The ability to read electrical activities from cells is the foundation of many biomedical procedures, such as brain activity mapping and neural prosthetics. Developing new tools for intracellular electrophysiology (the electric current running within cells) that push the limits of what is physically possible (spatiotemporal resolution) while reducing invasiveness could provide a deeper understanding of electrogenic cells and their networks in tissues, as well as new directions for human-machine interfaces.

My colleague Nicola Bagalà recently had the opportunity to interview Sergey Young, a board member of XPRIZE and the creator of the $100m Longevity Vision Fund. As you probably know, at the end of May this year XPrize hosted a 2-day workshop to better understand the bottlenecks and opportunities of the longevity industry, and in this interview, Sergey is sharing his vision on what can — and should — be done to accelerate the development of new therapies addressing aging.


We recently had the opportunity to interview Sergey Young, a board member of XPRIZE and the creator of the $100m Longevity Vision Fund.

When did you first become interested in healthy life extension, and why?

My interest began with a routine visit to a doctor. Five years ago, at the age of 42, my blood tests – which I neglected for 7 years, thinking I was in perfect health – showed that my cholesterol was extremely high, putting me at risk of one of the most common killers: heart disease.

Current guidelines recommend lowering cholesterol for heart disease risk reduction. New findings indicate that if cholesterol dips too low, it may boost the risk of hemorrhagic stroke, according to researchers.

Over a period of nine years, a Penn State-led study examined the relationship between —LDL, commonly known as “bad” —and hemorrhagic stroke. This type of stroke occurs when a blood vessel bursts in the brain.

The researchers found that participants with LDL cholesterol levels below 70 mg/dL had a higher risk of hemorrhagic stroke.

A particularly aggressive, metastasizing form of cancer, HER2-positive breast cancer, may be treated with nanoscopic particles “imprinted” with specific binding sites for the receptor molecule HER2. As reported by Chinese researchers in the journal Angewandte Chemie, the selective binding of the nanoparticles to HER2 significantly inhibits multiplication of the tumor cells.